BioSpace News Archive

One of the world’s largest efforts to find effective COVID-19 treatments will evaluate the impact of REGN-COV2 on mortality, hospital stays, and the need for ventilation Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and the University of Oxford today announced that RECOVERY (Randomised Evaluatio

Leverages proprietary pan-amyloid targeting agents with potential to diagnose and reverse the underlying pathology of systemic amyloid diseases, including AL and ATTR amyloidosis [14-September-2020] SOUTH SAN FRANCISCO, Calif. , Sept. 14, 2020 /PRNewswire/ -- Attralus, a biopharmaceutical company focused on creating transformative medicines to improve the lives of pat

Nevro Corp., a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, announced that it will establish global manufacturing operations in Costa Rica to invest in and support the Company’s future growth expectations.

Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor for the treatment of myelofibrosis, today announced that Dr. Stephen Dilly , President and CEO, will present an overview of the company at two investor conference

ESSA Pharma Inc. (NASDAQ: EPIX) (TSXV: EPI) (“ESSA” or the “Company”), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer today announced that the U.S. Food and Drug Administration (" FDA ") granted Fast Track Designation

Abiomed, Inc . (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the Raymond James North American Equities Conference (virtual) on Thursday, September 17th, 2020 at 10:30 am ET. ABOUT ABIOMED Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of

BLADE-CONQUER trial reached 120-subject enrollment goal Independent Data Monitoring Committee also recommended continuation of trial after planned review of blinded safety data Company expects topline results in 4Q-2020 SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Blade Therapeutics today announced that it has reached the 120-subject enrollment goal for the Phase 2 clinical study of the Company’s investigational therapeutic, BL

Evotec SE and the French-based BIOASTER Technological Research Institute announced that they have entered into a partnership to advance research for infectious diseases.

Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe viral infections, announced the appointment of Polly Murphy, D.V.M., Ph.D., Chief Business Officer of UroGen Pharma, to its Board of Directors.

Oazis to hold a virtual demo day on September 15 showcasing groundbreaking technologies of its six portfolio companies in the fields of health, advertising, sustainability and software